CFTR Modulators: Does One Dose Fit All?
Open Access
- 24 May 2021
- journal article
- review article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (6) , 458
Abstract
For many people with cystic fibrosis (pwCF), CFTR modulators will be the cornerstone of their treatment. These modulators show robust treatment effects at group level in pwCF with specific mutations. The individual effect however, is variable. In this review we will explain reasons for reconsideration of dosing regimens of CFTR modulating therapy in order to improve treatment response and prevent side effects. Since the effect of a drug depends on pharmacodynamics and pharmacokinetics, pharmacodynamics and pharmacokinetic properties of CFTR modulators will be discussed. Pharmacokinetic-pharmacodynamic relationships will be used to gain insight in dosage response and exposure response relationships. To understand the cause of variation in drug exposure, pharmacokinetic properties that may change due to CF disease will be explained. We show that with current insight, there are conceivable situations that give reason for reconsideration of dosing regimens, however many questions need to be unravelled.Keywords
This publication has 53 references indexed in Scilit:
- Airway Epithelial Inflammation In Vitro Augments the Rescue of Mutant CFTR by Current CFTR Modulator TherapiesFrontiers in Pharmacology, 2021
- CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision MedicineFrontiers in Pharmacology, 2020
- Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del AlleleNew England Journal of Medicine, 2019
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic FibrosisNew England Journal of Medicine, 2017
- Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delNew England Journal of Medicine, 2017
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTRNew England Journal of Medicine, 2015
- Cystic fibrosis: Insight into CFTR pathophysiology and pharmacotherapyClinical Biochemistry, 2012
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Cystic Fibrosis Since 1938American Journal of Respiratory and Critical Care Medicine, 2006